NURS 572 EXAM 40 QUESTIONS & CORRECT
ANSWERS LATEST 2026/2027
The strength of attraction between a drug and its receptor, drugs with high affinity
are strongly attracted to their receptor, drugs with low affinity are weakly
contracted. This affinity is reflected in its potency, high affinity is very potent -
ANSWER-Affinity
When the amount of drug eliminated between doses equals the dose administered,
average drug levels will remain constant and plateau will have been reached.
Repeated doses of equal size cause the drug to increase in body until plateau or
steady-state is obtained; plateau is reached in 4 half lives - ANSWER-Plateau or
steady state
rapid inactivation of certain oral drugs by the liver; if the liver can metabolize the
drug quickly it is rendered inactive with no effect - ANSWER-First-pass effect
to provide maximum benefit with minimum harm - ANSWER-therapeutic
objective of drug therapy
movement of a drug from its site of administration into the blood
Rate is influenced by chemical and physical properties and rate of dissolution,
surface area, blood flow, lipid solubility, and pH partitioning - ANSWER-drug
absorption
, movement of drugs from blood to interstitial space in tissue and onto the cells;
determined by blood flow to tissues; ability to exit vascular systems, ability to
enter cells; blood flow determines rate of distribution - ANSWER-drug distribution
chemical or enzymatic alteration of drug structure - ANSWER-drug metabolism
Removal of drugs from the body via urine, saliva, sweat, saliva, breast milk,
expired air
kidney is most important organ for excretion - ANSWER-drug excretion
for drugs with large half-lifes and when plateau must be achieved more quickly a
large initial dose may be administered - ANSWER-Loading dose
when plateau is achieved and needs to be maintained with smaller doses -
ANSWER-Maintenance doses
Remote Risk of Fetal Harm:
Controlled studies in women have been done and have failed to demonstrate a risk
of fetal harm during the first trimester, and there is no evidence of risk in later
trimesters - ANSWER-Category A drugs
Slightly More Risk Than A: Animal studies show no fetal risk, but controlled
studies have not been done in women
or Animal studies do show a risk of fetal harm, but controlled studies in women
have failed to demonstrate a risk during the first trimester, and there is no evidence
of risk in later trimesters. - ANSWER-Category B drugs
ANSWERS LATEST 2026/2027
The strength of attraction between a drug and its receptor, drugs with high affinity
are strongly attracted to their receptor, drugs with low affinity are weakly
contracted. This affinity is reflected in its potency, high affinity is very potent -
ANSWER-Affinity
When the amount of drug eliminated between doses equals the dose administered,
average drug levels will remain constant and plateau will have been reached.
Repeated doses of equal size cause the drug to increase in body until plateau or
steady-state is obtained; plateau is reached in 4 half lives - ANSWER-Plateau or
steady state
rapid inactivation of certain oral drugs by the liver; if the liver can metabolize the
drug quickly it is rendered inactive with no effect - ANSWER-First-pass effect
to provide maximum benefit with minimum harm - ANSWER-therapeutic
objective of drug therapy
movement of a drug from its site of administration into the blood
Rate is influenced by chemical and physical properties and rate of dissolution,
surface area, blood flow, lipid solubility, and pH partitioning - ANSWER-drug
absorption
, movement of drugs from blood to interstitial space in tissue and onto the cells;
determined by blood flow to tissues; ability to exit vascular systems, ability to
enter cells; blood flow determines rate of distribution - ANSWER-drug distribution
chemical or enzymatic alteration of drug structure - ANSWER-drug metabolism
Removal of drugs from the body via urine, saliva, sweat, saliva, breast milk,
expired air
kidney is most important organ for excretion - ANSWER-drug excretion
for drugs with large half-lifes and when plateau must be achieved more quickly a
large initial dose may be administered - ANSWER-Loading dose
when plateau is achieved and needs to be maintained with smaller doses -
ANSWER-Maintenance doses
Remote Risk of Fetal Harm:
Controlled studies in women have been done and have failed to demonstrate a risk
of fetal harm during the first trimester, and there is no evidence of risk in later
trimesters - ANSWER-Category A drugs
Slightly More Risk Than A: Animal studies show no fetal risk, but controlled
studies have not been done in women
or Animal studies do show a risk of fetal harm, but controlled studies in women
have failed to demonstrate a risk during the first trimester, and there is no evidence
of risk in later trimesters. - ANSWER-Category B drugs
